Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclic GMP–AMP synthase (cGAS) is a cytosolic enzyme that functions as a DNA sensor, playing a central role in the innate immune response to cytosolic double-stranded DNA (dsDNA). Upon binding to dsDNA, cGAS catalyzes the synthesis of cyclic GMP-AMP (cGAMP), specifically 2′,3′-cGAMP, from ATP and GTP. This cyclic dinucleotide acts as a second messenger that activates the adaptor protein STING (Stimulator of Interferon Genes), leading to downstream signaling events including activation of TBK1 and IRF3, which ultimately induce type I interferon production. Dysregulation is linked to autoimmune diseases; targeted stimulation has potential applications in immuno-oncology.
Inhibition of cGAS activity; Activation of cGAS activity (in immuno-oncology)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic GMP–AMP synthase (None).